Global central precocious puberty (CPP) treatment market is projected to register a healthy CAGR of 7.1% in the forecast period of 2020 to 2027. The new market report contains data for the historic year 2018, the base year of calculation is 2019 and the forecast period is 2020 to 2027.
Market Segmentation:
Global Central Precocious Puberty (CPP) Treatment Market, By Type (Medication, Surgery), Month (1-Month, 2-Month, 6-Month, Others), Route of Administration (Parenteral, Implants, Oral, Others), Gender (Girls, Boys), End User (Hospitals, Specialty Clinics, Homecare, Others), Distribution Channel (Direct Tender, Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Others), Country (U.S., Canada, Mexico, Germany, U.K., France, Italy, Spain, Switzerland, Netherlands, Russia, Turkey, Austria, Norway, Hungary, Lithuania, Ireland, Poland, Rest of Europe, Japan, China, India, South Korea, Australia, Singapore, Thailand, Malaysia, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific, Brazil, Argentina, Peru, Rest of South America, South Africa, Saudi Arabia, U.A.E., Israel, Egypt, Kuwait, Rest of Middle East and Africa) – Industry Trends & Forecast to 2027
Some of the major factors contributing to the growth of global central precocious puberty (CPP) treatment market are:

• Growing prevalence of hormonal disorders
• Increasing prevalence of obesity
Market Players:

The key market players for global central precocious puberty (CPP) treatment market are listed below:

• Ipsen Pharma
• AbbVie Inc.
• Mylan N.V.
• Pfizer Inc.
• Zydus Pharmaceuticals, Inc. (a subsidiary of Zydus Cadila)
• Teva Pharmaceutical USA, Inc. (a subsidiary of Teva Pharmaceutical Industries Ltd.)
• Takeda Pharmaceutical Company Limited
• Sanofi
• Arbor Pharmaceuticals
• Tolmar Pharmaceuticals, Inc.
• GP Pharm
• Debiopharm
• DAEWOONG PHARMACEUTICAL CO.,LTD
• AstraZeneca
• Sun Pharmaceutical Industries Ltd
• Endo International plc